CervoMed Inc.

CervoMed Inc. reported a net loss of $27.0 million for fiscal year 2025, an increase from a $16.3 million loss in 2024. The company generated $4.0 million in grant revenue, a significant decrease from $9.7 million in the prior year. Research and development expenses increased to $21.8 million from $18.8 million, primarily driven by clinical trial activities for its lead drug candidate neflamapimod in Dementia with Lewy Bodies (DLB), frontotemporal disorders, and recovery after stroke. General and administrative expenses also rose to $10.5 million. The company ended the year with $20.9 million in cash, cash equivalents, and marketable securities, down from $38.9 million at the end of 2024. Management notes substantial doubt about the company's ability to continue as a going concern and will require additional capital to fund operations, including a planned Phase 3 trial in DLB.

Key Takeaways